Investors with the goal of beating the broader market often turn to stock selection. Strategic choices in individual stocks can have a profound impact on your wealth.

Viridian Therapeutics Inc (NASDAQ: VRDN) closed the day trading at $18.11 down -2.32% from the previous closing price of $18.54. In other words, the price has decreased by -$2.32 from its previous closing price. On the day, 0.64 million shares were traded. VRDN stock price reached its highest trading level at $18.96 during the session, while it also had its lowest trading level at $17.961.

Ratios:

For a better understanding of VRDN, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 11.01 and its Current Ratio is at 11.01. In the meantime, Its Debt-to-Equity ratio is 0.04 whereas as Long-Term Debt/Eq ratio is at 0.03.

Upgrades & Downgrades

In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Wells Fargo on December 19, 2024, Downgraded its rating to Equal Weight and sets its target price to $27 from $37 previously.

Needham reiterated its Buy rating for the stock on September 11, 2024, while the target price for the stock was revised from $30 to $38.

Insider Transactions:

The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Sep 27 ’24 when Beetham Thomas W. bought 5,000 shares for $23.41 per share. The transaction valued at 117,050 led to the insider holds 6,000 shares of the business.

Mahoney Stephen F. bought 21,400 shares of VRDN for $499,262 on Sep 27 ’24. The President and CEO now owns 21,400 shares after completing the transaction at $23.33 per share. On Sep 13 ’24, another insider, Fairmount Funds Management LLC, who serves as the Director of the company, bought 1,600,000 shares for $18.75 each. As a result, the insider paid 30,000,000 and bolstered with 3,445,813 shares of the company.

Valuation Measures:

Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, VRDN now has a Market Capitalization of 1478906112 and an Enterprise Value of 1127515520. For the stock, the TTM Price-to-Sale (P/S) ratio is 4929.70 while its Price-to-Book (P/B) ratio in mrq is 4.53. Its current Enterprise Value per Revenue stands at 3696.772 whereas that against EBITDA is -3.038.

Stock Price History:

The Beta on a monthly basis for VRDN is 0.58, which has changed by 0.15350318 over the last 52 weeks, in comparison to a change of 0.15222645 over the same period for the S&P500. Over the past 52 weeks, VRDN has reached a high of $27.20, while it has fallen to a 52-week low of $9.90. The 50-Day Moving Average of the stock is 10.59%, while the 200-Day Moving Average is calculated to be 7.79%.

Shares Statistics:

Over the past 3-months, VRDN traded about 751.40K shares per day on average, while over the past 10 days, VRDN traded about 880350 shares per day. A total of 81.65M shares are outstanding, with a floating share count of 73.55M. Insiders hold about 9.94% of the company’s shares, while institutions hold 106.23% stake in the company. Shares short for VRDN as of 1753920000 were 11675434 with a Short Ratio of 15.54, compared to 1751241600 on 10778607. Therefore, it implies a Short% of Shares Outstanding of 11675434 and a Short% of Float of 14.940000000000001.

Earnings Estimates

Viridian Therapeutics Inc (VRDN) is currently under the scrutiny of 11.0 analysts, each contributing to the ongoing evaluation of its stock.The consensus estimate for the next quarter is -$1.06, with high estimates of -$0.42 and low estimates of -$1.36.

Analysts are recommending an EPS of between -$2.96 and -$4.97 for the fiscal current year, implying an average EPS of -$4.04. EPS for the following year is -$3.96, with 11.0 analysts recommending between -$2.9 and -$4.99.